Ecopipam for Tourette Syndrome: A Randomized Trial

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Current Tourette syndrome (TS) treatments, primarily antipsychotics, carry risks of weight gain, metabolic changes, and movement disorders.
• Ecopipam, a selective dopamine 1 receptor antagonist, has shown promise in small trials for tic reduction with a potentially better safety profile.
• This study aimed to further assess ecopipam's efficacy and safety in pediatric TS patients.

Purpose of the Study:

• To evaluate the efficacy of ecopipam in reducing tics in children and adolescents with moderate to severe Tourette syndrome.
• To assess the safety and tolerability of ecopipam compared to placebo.
• To compare the adverse event profiles between ecopipam and placebo groups.

Main Methods:

• A multicenter, randomized, double-blind, placebo-controlled, phase 2b trial.
• Inclusion of subjects aged 6 to 17 years with moderate to severe Tourette syndrome (Yale Global Tic Severity Score ≥20).
• Random assignment to ecopipam or placebo for 12 weeks, with primary endpoint as change in Yale Global Tic Severity Score.

Main Results:

• Ecopipam demonstrated a statistically significant reduction in total tic scores compared to placebo over 12 weeks (P = .01).
• Greater improvement was observed in the Clinical Global Impression of Tourette Syndrome Severity in the ecopipam group (P = .03).
• Weight gain was more prevalent in the placebo group; no significant metabolic or ECG changes were noted. Common adverse events included headache, insomnia, fatigue, and somnolence.

Conclusions:

• Ecopipam effectively reduces tics in pediatric patients with Tourette syndrome.
• The drug shows a favorable safety profile, lacking common antipsychotic-associated side effects.
• Ecopipam represents a promising alternative treatment for Tourette syndrome in children and adolescents.